Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data

References

• Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.
   PubMed Web of Science ®Google Scholar
• Inman BA, Harrison MR, George DJ. Novel immunotherapeutic strategies in development for renal cell carcinoma. Eur Urol. 2013;63:881–889.
   PubMed Web of Science ®Google Scholar
• Meskawi M, Sun M, Trinh QD, et al. A review of integrated staging systems for renal cell carcinoma. Eur Urol. 2012;62:303–314.
   PubMed Web of Science ®Google Scholar
• Wolff I, May M, Hoschke B, et al. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database. Eur J Surg Oncol. 2016;42:744–750.
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Le V, Cao D, et al. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. J Pathol. 2018;244:525–537.
   PubMed Web of Science ®Google Scholar
• Ricketts CJ, De Cubas AA, Fan H, et al. The cancer genome atlas comprehensive molecular characterization of renal cell Carcinoma. Cell Rep. 2018;23:313–26 e5.
   PubMed Web of Science ®Google Scholar
• Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010;463(7280):457–463.
   PubMed Web of Science ®Google Scholar
• Baralle FE, Giudice J. Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017;18:437–451.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu J, Huang BO, et al. Mechanism of alternative splicing and its regulation. Biomed Rep. 2015;3:152–158.
   PubMed Web of Science ®Google Scholar
• Gallego-Paez LM, Bordone MC, Leote AC, et al. Alternative splicing: the pledge, the turn, and the prestige: the key role of alternative splicing in human biological systems. Hum Genet. 2017;136:1015–1042.
   PubMed Web of Science ®Google Scholar
• Martinez-Montiel N, Rosas-Murrieta NH, Anaya Ruiz M, et al. Alternative splicing as a target for cancer treatment. Int J Mol Sci. 2018;19. DOI:10.3390/ijms19020545
   PubMed Web of Science ®Google Scholar
• Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy. Oncogene. 2015;34:1–14.
   PubMed Web of Science ®Google Scholar
• Kornblihtt AR, Schor IE, Allo M, et al. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol. 2013;14:153–165.
   PubMed Web of Science ®Google Scholar
• Song X, Zeng Z, Wei H, et al. Alternative splicing in cancers: from aberrant regulation to new therapeutics. Semin Cell Dev Biol. 2018;75:13–22.
   PubMed Web of Science ®Google Scholar
• Tsai YS, Dominguez D, Gomez SM, et al. Transcriptome-wide identification and study of cancer-specific splicing events across multiple tumors. Oncotarget. 2015;6:6825–6839.
   PubMedGoogle Scholar
• Sebestyen E, Zawisza M, Eyras E. Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. Nucleic Acids Res. 2015;43:1345–1356.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19:A68–77.
   PubMedGoogle Scholar
• Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Cleland J, Kim R, et al. SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts. Bioinformatics. 2012;28(18):2385–2387.
   PubMed Web of Science ®Google Scholar
• Ryan M, Wong WC, Brown R, et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 2016;44:D1018–22.
   PubMed Web of Science ®Google Scholar
• Troyanskaya O, Cantor M, Sherlock G, et al. Missing value estimation methods for DNA microarrays. Bioinformatics (Oxford, England). 2001;17(6):520–525.
   PubMed Web of Science ®Google Scholar
• Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics. 2017;33:2938–2940.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang L-G, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Friedman JH, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1-22.
   Google Scholar
• Simon N, Friedman J, Hastie T, et al. Regularization paths for Cox’s proportional hazards model via coordinate descent. J Stat Softw. 2011;39:1–13.
   PubMed Web of Science ®Google Scholar
• Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381–5397.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173–e80.
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–1370.
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Vickers AJ. Decision curve analysis: a discussion. Med Decis Making. 2008;28:146–149.
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26:565–574.
   PubMed Web of Science ®Google Scholar
• Van Calster B, Wynants L, Verbeek JFM, et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol. 2018;74:796–804.
   PubMed Web of Science ®Google Scholar
• Fitzgerald M, Saville BR, Lewis R. Decision curve analysis. JAMA. 2015;313:409–410.
   Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–425.
   PubMed Web of Science ®Google Scholar
• Piva F, Giulietti M, Burini AB, et al. SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum Mutat. 2012;33:81–85.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Deng Y, Wang K, et al. Profiles of alternative splicing in colorectal cancer and their clinical significance: a study based on large-scale sequencing data. EBioMedicine. 2018;36:183–195.
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
   PubMed Web of Science ®Google Scholar
• Ge Y, Weygant N, Qu D, et al. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018;143:1162–1175.
   PubMed Web of Science ®Google Scholar
• Bates DJCR VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. 2002;62.
   Google Scholar
• Jiang J, Chen X, Liu H, et al. Polypyrimidine tract-binding protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM. Am J Cancer Res. 2017;7(2):245-59.
   Google Scholar
• Chen K, Xiao H, Zeng J, et al. Alternative splicing of EZH2 pre-mRNA by SF3B3 contributes to the tumorigenic potential of renal cancer. Clin Cancer Res. 2017;23:3428–3441.
   PubMed Web of Science ®Google Scholar
• Bianchi C, Bombelli S, Raimondo F, et al. Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of Annexin A3. Am J Pathol. 2010;176:1660–1670.
   PubMed Web of Science ®Google Scholar
• Feng X, Zhang L, Tu W, et al. Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014: a SEER-based analysis. Medicine (Baltimore). 2019;98:e16684.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–137.
   PubMed Web of Science ®Google Scholar
• Qu M, Yu J, Liu H, et al. The candidate tumor suppressor gene SLC8A2 inhibits invasion, angiogenesis and growth of glioblastoma. Mol Cells. 2017;40:761–772.
   PubMed Web of Science ®Google Scholar
• Lin P, He RQ, Ma FC, et al. Systematic analysis of survival-associated alternative splicing signatures in gastrointestinal pan-adenocarcinomas. EBioMedicine. 2018;34:46–60.
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen Z, Yong L. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol. 2018;148:368–374.
   PubMed Web of Science ®Google Scholar
• Lehmann KV, Kahles A, Kandoth C, et al. Integrative genome-wide analysis of the determinants of RNA splicing in kidney renal clear cell carcinoma. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing. 2015;20:44-55.
   Google Scholar
• Yun CW, Lee SH. The roles of autophagy in cancer. Int J Mol Sci. 2018;19(11):3466.
   Google Scholar
• Rajendran P, Alzahrani AM, Hanieh HN, et al. Autophagy and senescence: a new insight in selected human diseases. J Cell Physiol. 2019;234(12):21485–21492.
   PubMed Web of Science ®Google Scholar
• Hall DP, Cost NG, Hegde S, et al. TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell. 2014;26:738–753.
   PubMed Web of Science ®Google Scholar
• Mizutani A, Koinuma D, Seimiya H, et al. The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma. Oncogene. 2016;35(27):3514–3523.
   PubMed Web of Science ®Google Scholar
• Carpenter B, MacKay C, Alnabulsi A, et al. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta. 2006;1765:85–100.
   PubMed Web of Science ®Google Scholar
• Rydzanicz M, Wrzesinski T, Bluyssen HA, et al. Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. Cancer Lett. 2013;341:111–126.
   PubMed Web of Science ®Google Scholar